Abstract: The disclosure relates to methods for therapeutically targeting circulating tumor cells during hemodialysis, comprising: connecting a patient's bloodstream to a flow electroporator device, the device comprising: an array of polymeric channels, where the opposing sidewalls of each channel are lined with discontinuous sections of electrodes, interspersed by non-conductive polymer sections to generate sequential electric fields by constant direct current voltages; sequential electric fields with independently regulated intensity, duration, and polarity to induce lysis of circulating tumor cells and deliver chemotherapeutic agents to reduce the viability of circulating tumor cells; and polymeric tubing inlet and outlet for seamless integration into the bloodline tubing of any hemodialysis machine

Abstract: The present disclosure relates to compositions of phytonutrients and methods of treating obesity by administering these compositions to subjects in need thereof. The compositions described herein are rationally designed compositions of phytonutrients that interfere with fat cell differentiation, a process commonly known as “adipogenesis”, to prevent weight gain and improve glycemic control. The phytonutrients are rationally combined based on their complementary effects on the expression level of six adipogenic biomarker proteins. Exemplary compositions can include one or more of berberine, luteolin, resveratrol, fisetin, quercetin, fucoidan, epigallocatechin gallate (EGCG), hesperidin, or curcumin.

Abstract: The present disclosure relates to compositions of phytonutrients and methods of treating diabetes by administering these compositions to subjects in need thereof. The compositions described herein are rationally designed compositions of phytonutrients that promote insulin sensitivity and have weight-loss potential. The compositions include formulation of rationally combined phytonutrients for diabetes treatment and management. Using nanofluidic proteomics, phytonutrients were classified as insulin sensitizing or anti-adipogenic based on their ability to enhance insulin-stimulated Akt2 phosphorylation and glucose uptake or inhibit adipogenesis, respectively. In some embodiments, the formulation includes a synergistic amount of insulin-sensitizing phytonutrients cinnamaldehyde and curcumin.

Abstract: The present invention is directed towards methods for therapeutically targeting circulating tumor cells during hemodialysis.

Abstract: The present invention is directed towards methods for treating non-alcoholic fatty liver disease (NAFLD) in a patient and determining prognosis of NAFLD in a patient.

Abstract: The present invention is directed towards methods for treating non-alcoholic fatty liver disease (NAFLD) in a patient and determining prognosis of NAFLD in a patient.

Abstract: The present invention is directed towards methods for therapeutically targeting circulating tumor cells during hemodialysis.

Abstract: Provided are methods and compositions for treatment of cancer. In particular, these methods and compositions may include an inhibitor of a deubiquitinating enzyme. In certain aspects, these methods and compositions may include a modulator of glucose metabolism. Also provided are methods of assaying the glucose content of cells and tissues using detection of uH2B.